| Gene symbol | CD22 | Synonyms | SIGLEC-2, SIGLEC2 | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19q13.12 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD22 molecule | ||||
| GTO ID | GTC2182 |
| Trial ID | NCT04088864 |
| Disease | Lymphoma | Childhood B-Cell Acute Lymphoblastic Leukemia | B-Cell Lymphoma |
| Altered gene | CD22 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD22 CAR-T cells |
| Phase | Phase1 |
| Recruitment status | Suspended |
| Title | CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies |
| Year | 2020 |
| Country | United States |
| Company sponsor | Stanford University |
| Other ID(s) | IRB-50878|CCT6003|IRB-50878|NCI-2019-07285 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||||||
|
|||||||||||||